Prostate Cancer Trial, Recruiting NCT06353321 Sponsor: University of Texas Southwestern Medical Center Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06353321
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men who have been diagnosed with prostate cancer (specifically a type called adenocarcinoma) and are already scheduled to have a standard PSMA-PET scan as part of their routine care, either to check the cancer at the time of first diagnosis or to look for signs that the cancer has come back or progressed

Who may not be able to join:

  • People who have a known mental health condition or substance use disorder that, in the treating doctor's opinion, could interfere with taking part in the study
  • People who weigh more than 450 pounds (approximately 204 kg), due to the weight limit of the scanning equipment used in the trial
  • People with a serious uncontrolled illness — such as an active infection, heart failure with symptoms, unstable chest pain, an irregular heartbeat, or other medical or personal circumstances — that, in the treating doctor's opinion, would make it difficult to follow the study requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Neil Desai, MD, University of Texas Southwestern Medical Center

Phone: 214 648-1836

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
12 December 2024
Est. completion
12 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Qualitative assessment of RefleXion X1 imaging performance with Illuccix PSMA PET imaging agent immediately following a standard of care Illuccix PET/CT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov